Halozyme Therapeutics Inc. (NASDAQ:HALO) went up by 4.15% from its latest closing price compared to the recent 1-year high of $45.76. The company’s stock price has collected 3.75% of gains in the last five trading sessions. Press Release reported on 01/11/21 that Halozyme Provides 2021 Financial Guidance Highlighted By Strong Revenue And EPS Growth
Is It Worth Investing in Halozyme Therapeutics Inc. (NASDAQ :HALO) Right Now?
Halozyme Therapeutics Inc. (NASDAQ:HALO) scored a price-to-earnings ratio above its average ratio, recording 294.97 x from its present earnings ratio. Plus, the 36-month beta value for HALO is at 1.53. Opinions of the stock are interesting as 10 analysts out of 12 who provided ratings for Halozyme Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 1 as “sell.”
The average price from analysts is $42.00, which is -$3.88 below the current price. HALO currently public float of 130.49M and currently shorts hold a 11.85% ratio of that float. Today, the average trading volume of HALO was 1.94M shares.
HALO’s Market Performance
HALO stocks went up by 3.75% for the week, with a monthly jump of 9.94% and a quarterly performance of 59.64%, while its annual performance rate touched 127.01%. The volatility ratio for the week stands at 5.61% while the volatility levels for the past 30 days are set at 4.00% for Halozyme Therapeutics Inc.. The simple moving average for the period of the last 20 days is 5.58% for HALO stocks with a simple moving average of 54.49% for the last 200 days.
Analysts’ Opinion of HALO
Many brokerage firms have already submitted their reports for HALO stocks, with Berenberg repeating the rating for HALO by listing it as a “Buy.” The predicted price for HALO in the upcoming period, according to Berenberg is $50 based on the research report published on December 17th of the previous year 2020.
JP Morgan, on the other hand, stated in their research note that they expect to see HALO reach a price target of $28. The rating they have provided for HALO stocks is “Overweight” according to the report published on September 14th, 2020.
The Benchmark Company gave a rating of “Buy” to HALO, setting the target price at $39 in the report published on July 01st of the previous year.
HALO Trading at 12.81% from the 50-Day Moving Average
After a stumble in the market that brought HALO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -1.38% of loss for the given period.
Volatility was left at 4.00%, however, over the last 30 days, the volatility rate increased by 5.61%, as shares surge +7.84% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +61.18% upper at present.
During the last 5 trading sessions, HALO rose by +3.75%, which changed the moving average for the period of 200-days by +148.24% in comparison to the 20-day moving average, which settled at $42.91. In addition, Halozyme Therapeutics Inc. saw 5.67% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at HALO starting from Kelley Kenneth J, who sale 5,000 shares at the price of $42.91 back on Jan 04. After this action, Kelley Kenneth J now owns 194,833 shares of Halozyme Therapeutics Inc., valued at $214,556 using the latest closing price.
LaBarre Michael J., the SVP, Chief Technical Officer of Halozyme Therapeutics Inc., sale 12,000 shares at $42.58 during a trade that took place back on Dec 21, which means that LaBarre Michael J. is holding 122,800 shares at $510,919 based on the most recent closing price.
Stock Fundamentals for HALO
Current profitability levels for the company are sitting at:
- -18.70 for the present operating margin
- +76.76 for the gross margin
The net margin for Halozyme Therapeutics Inc. stands at -36.86. The total capital return value is set at -8.43, while invested capital returns managed to touch -19.05. Equity return is now at value 24.30, with 4.10 for asset returns.
Based on Halozyme Therapeutics Inc. (HALO), the company’s capital structure generated 438.72 points at debt to equity in total, while total debt to capital is 81.44. Total debt to assets is 71.14, with long-term debt to equity ratio resting at 417.42. Finally, the long-term debt to capital ratio is 77.48.
When we switch over and look at the enterprise to sales, we see a ratio of 12.96, with the company’s debt to enterprise value settled at 0.16. The receivables turnover for the company is 4.38 and the total asset turnover is 0.39. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.35.